Certara completed the acquisition of Pinnacle 21 for $310m.

Certara, a biosimulation company, completed the acquisition of Pinnacle 21, a provider of software for preparing clinical trial data for regulatory submission, for $310m. "Certara is the ideal partner for Pinnacle 21’s exceptional team and customer base. Both companies empower customers to collect, validate, and analyze data to inform critical decisions in drug development and achieve regulatory success. Joining forces with Certara tightens the link between clean data and informed analysis. We are eager to integrate and expand our software platforms to continue our mission to speed up lifesaving therapies to patients," Max Kanevsky, Pinnacle 21 Founder and CEO.